Exact Mass: 423.317083
Exact Mass Matches: 423.317083
Found 118 metabolites which its exact mass value is equals to given mass value 423.317083,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alpha-Tocotrienoxyl radical
This compound belongs to the family of Diterpenes. These are terpene compounds formed by four isoprene units.
O-Linoleoylcarnitine
C25H45NO4 (423.33484100000004)
O-Linoleoylcarnitine is an acylcarnitine. More specifically, it is an linoleic ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-Linoleoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-Linoleoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular O-Linoleoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(10Z,12Z)-octadeca-10,12-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(10Z,12Z)-octadeca-10,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (10Z,12Z)-octadeca-10,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10Z,12Z)-octadeca-10,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10Z,12Z)-octadeca-10,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9Z,11E)-Octadeca-9,11-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(9Z,11E)-octadeca-9,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,11E)-octadeca-9,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,11E)-octadeca-9,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,11E)-octadeca-9,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z,11E)-octadeca-9,11-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6Z,9Z)-Octadeca-6,9-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(6Z,9Z)-octadeca-6,9-dienoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z)-octadeca-6,9-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z)-octadeca-6,9-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,9Z)-octadeca-6,9-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (6Z,9Z)-octadeca-6,9-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E,4E)-Octadeca-2,4-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(2E,4E)-octadeca-2,4-dienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E)-octadeca-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E)-octadeca-2,4-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,4E)-octadeca-2,4-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (2E,4E)-octadeca-2,4-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-(3-Methyl-5-propylfuran-2-yl)nonanoylcarnitine
C24H41NO5 (423.29845760000006)
9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(3-methyl-5-propylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-(5-Heptyl-3-methylfuran-2-yl)pentanoylcarnitine
C24H41NO5 (423.29845760000006)
5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-(5-heptyl-3-methylfuran-2-yl)pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine
C24H41NO5 (423.29845760000006)
7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(3-methyl-5-pentylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-(5-Pentylfuran-2-yl)octanoylcarnitine
C24H41NO5 (423.29845760000006)
8-(5-Pentylfuran-2-yl)octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-(5-pentylfuran-2-yl)octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-(5-Pentylfuran-2-yl)octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-(5-Pentylfuran-2-yl)octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Gallamonum
C24H45N3O3 (423.34607400000004)
2-(indol-3-yl)ethyl octadeca-9Z,12Z-dienoate
C28H41NO2 (423.31371260000003)
(6S,7R,10E,14E)-16-(1H-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol
C28H41NO2 (423.31371260000003)
N-demethylteleocidin A1|N13-desmethylteleocidin A-1
Linoleyl carnitine
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE0; CorrDec
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE10; CorrDec
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE30; CorrDec
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE0; MS2Dec
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE10; MS2Dec
C25H45NO4 (423.33484100000004)
Linoleyl-carnitine; AIF; CE30; MS2Dec
C25H45NO4 (423.33484100000004)
2-Hydroxy-6-pentadecyl-N-phenylbenzamide
C28H41NO2 (423.31371260000003)
arachidonoyl-(2-phenoxyethyl)amide
C28H41NO2 (423.31371260000003)
Gallamine
C24H45N3O3 (423.34607400000004)
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent
Octadecadienoylcarnitine
benzyldimethylstearylammonium chloride
C27H50ClN (423.36315700000006)
N,N-BIS(2-HYDROXYETHYL)-N-METHYLHEXADECAN-1-AMINIUM BROMIDE
mecetronium etilsulfate
C22H49NO4S (423.3382114000001)
C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent
2-(dicyclohexylphosphino)-6-methoxy-N,N-dimethylbiphenyl-2-amine
Phosphonic acid 2-dodecanoylamino-hexyl ester propyl ester
C20H42NO6P (423.27496020000007)
O-linoleyl-L-carnitine
C25H45NO4 (423.33484100000004)
An O-octadecadienoyl-L-carnitine where the acyl group specified is linoleyl.
8-(5-Pentylfuran-2-yl)octanoylcarnitine
C24H41NO5 (423.29845760000006)
9-(3-Methyl-5-propylfuran-2-yl)nonanoylcarnitine
C24H41NO5 (423.29845760000006)
5-(5-Heptyl-3-methylfuran-2-yl)pentanoylcarnitine
C24H41NO5 (423.29845760000006)
7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine
C24H41NO5 (423.29845760000006)
(6Z,9Z)-Octadeca-6,9-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(2E,4E)-Octadeca-2,4-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(9Z,11E)-Octadeca-9,11-dienoylcarnitine
C25H45NO4 (423.33484100000004)
(10Z,12Z)-octadeca-10,12-dienoylcarnitine
C25H45NO4 (423.33484100000004)
3beta-(2-Diethylaminoethoxy)androst-5-en-17-one hydrochloride
C25H42ClNO2 (423.29039020000005)
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D009676 - Noxae > D000963 - Antimetabolites D004791 - Enzyme Inhibitors
cyclopentyl-[(8R,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone
cyclopentyl-[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone
3-Octadeca-9,12-dienoyloxy-4-(trimethylazaniumyl)butanoate
C25H45NO4 (423.33484100000004)
2-aminoethyl [2-hydroxy-3-[(Z)-pentadec-9-enoxy]propyl] hydrogen phosphate
C20H42NO6P (423.27496020000007)
(2S,3R)-2-(Acetylamino)octadecane-1,3-diol 1-phosphoric acid
C20H42NO6P (423.27496020000007)
(3E)-3-[1-amino-3-methyl-5-[(E)-2-methyltetradec-4-en-6,8-diynyl]pyrrolidin-2-ylidene]-1,5-dimethylpyrrolidine-2,4-dione
O-linoleoylcarnitine
C25H45NO4 (423.33484100000004)
An O-acylcarnitine having linoleoyl as the acyl substituent.
3-[(9E,12E)-octadeca-9,12-dienoyloxy]-4-(trimethylazaniumyl)butanoate
C25H45NO4 (423.33484100000004)
N-(2-phenoxy-ethyl) arachidonoyl amine
C28H41NO2 (423.31371260000003)
O-octadecadienoylcarnitine
C25H45NO4 (423.33484100000004)
An O-acylcarnitine in which the acyl group specified is octadecadienoyl.
O-octadecadienoyl-L-carnitine
C25H45NO4 (423.33484100000004)
An O-acyl-L-carnitine that is L-carnitine having a octadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.
O-linoelaidylcarnitine
C25H45NO4 (423.33484100000004)
An O-octadecadienoylcarnitine having linoelaidyl as the acyl substituent.
LPC(12:1)
C20H42NO6P (423.27496020000007)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
SPHP(21:0)
C21H46NO5P (423.31134360000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
NA-Histamine 22:5(7Z,10Z,13Z,16Z,19Z)
C27H41N3O (423.32494560000004)
7-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine
(10s,13s)-5-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol
(3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-2,3'a,4',5,5',6,6',6a,6b,7,7',7'a,8,11a-tetradecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-3,11-dione
C27H37NO3 (423.27732920000005)
7-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine
8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol
C28H41NO2 (423.31371260000003)
3-{[(1s,2r,4ar,4bs,7s,8r,8as,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol
C28H41NO2 (423.31371260000003)
(3z,5z,7z,11z,13z,15z,17z)-20-[(2e)-hex-2-en-1-yl]-7,15-dimethyl-1-azacycloicosa-1,3,5,7,11,13,15,17-octaene-2,9,10-triol
C27H37NO3 (423.27732920000005)
n-{2-[(3r,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-1,6-diene-3-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
(10s)-10-{2-[(1as,4ar,5s,6s,8as)-1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol
n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
2-(1h-indol-3-yl)ethyl (9z,12z)-octadeca-9,12-dienoate
C28H41NO2 (423.31371260000003)
(3'r,3'as,6's,6as,7'ar,9r,11br)-3',6',10,11b-tetramethyl-2,3'a,4',5,5',6,6',6a,6b,7,7',7'a,8,11a-tetradecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-3,11-dione
C27H37NO3 (423.27732920000005)
(5as,5br,7as,11as,11br,13s,13ar)-2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate
C28H41NO2 (423.31371260000003)
3',6',10,11b-tetramethyl-2,3'a,4',5,5',6,6',6a,6b,7,7',7'a,8,11a-tetradecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-3,11-dione
C27H37NO3 (423.27732920000005)
(10s)-10-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol
3-{[(1s,2r,4ar,4br,7s,8r,8ar,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol
C28H41NO2 (423.31371260000003)
2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate
C28H41NO2 (423.31371260000003)
7-[(2e)-5-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl]-9-methyl-8h-purin-6-amine
(1s,4r,4as,7r,8s,8as)-8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol
C28H41NO2 (423.31371260000003)
n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
(10s)-10-{2-[(1s,2r,4ar,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol
n-{2-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-diene-1-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
3-[(7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl)methyl]-1h-indol-6-ol
C28H41NO2 (423.31371260000003)
n-{2-[(6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
16-(1h-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol
C28H41NO2 (423.31371260000003)
(10s)-10-{2-[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol
5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol
n-{2-[(2e,6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine
C23H41N3O2S (423.29193260000005)
(3e,5e,7e,11z,13e,15e,17e)-20-[(2e)-hex-2-en-1-yl]-7,15-dimethyl-1-azacycloicosa-1,3,5,7,11,13,15,17-octaene-2,9,10-triol
C27H37NO3 (423.27732920000005)
2-(1h-indol-3-yl)ethyl octadeca-9,12-dienoate
C28H41NO2 (423.31371260000003)